Novo Nordisk's real problem is not the compounders

ON AUGUST 6TH a federal judge in Texas dismissed an antitrust lawsuit brought against Novo Nordisk and Eli Lilly by a compounding pharmacy that wanted to keep selling copycat versions of their GLP-1 weight-loss drugs. Senior Judge Micaela Alvarez of the Western District of Texas ruled that Strive Specialties had failed to demonstrate that its compounded semaglutide was reasonably interchangeable with Novo Nordisk's branded product, and so suffered no antitrust injury. Strive said it was evaluating an appeal. The stock market barely noticed.

That is because the dismissal was ceremonial. The protection Novo Nordisk wanted from this case — the right to exclude unapproved copies of semaglutide — was already secure through regulation. The judge merely confirmed what the Food and Drug Administration had established more than a year ago.

Compounding is the practice by which pharmacies prepare personalised versions of medications, traditionally for patients who need a dose, formulation or allergen-free version that is not commercially available. During the GLP-1 shortages of 2022 to 2024, when demand for semaglutide and tirzepatide vastly outstripped branded supply, compounders were legally permitted to produce copies. They sold compounded semaglutide for $150-$300 a month, compared with more than $1,000 for the branded product. The arrangement created a large secondary market that the manufacturers had no interest in preserving.

The FDA declared the semaglutide shortage resolved in February 2025 and set enforcement deadlines for compounders to wind down. Those deadlines have long since passed. In May 2026 the agency went further, proposing a rule to permanently bar the largest compounding facilities from producing semaglutide or tirzepatide under any circumstances. The legal framework that matters, in other words, is administrative, not antitrust.

To be sure, antitrust suits can sometimes succeed where regulation has not yet caught up. The point of Strive's case was to argue that Novo Nordisk and Eli Lilly had entered exclusive deals with telehealth providers to block compounded prescriptions, thereby suppressing competition. Judge Alvarez's ruling rejected that framing. Antitrust law protects competition, not individual competitors, and compounded GLP-1s that are legally permissible only for narrow medical exceptions do not belong in the same product market as the branded originals. The reasoning is unassailable: if a drug can be compounded only when a physician certifies that the branded version cannot meet a patient's needs, the two products are not substitutes in any ordinary sense.

The antitrust dismissal is a tidy conclusion to a chapter that closed when the shortages ended. But the real questions facing Novo Nordisk have nothing to do with pharmacy compounders.

On August 4th the company reported second-quarter results and raised its full-year guidance. Adjusted sales grew 7% to 78.5bn kroner ($12bn), with operating profit up 11%. The firm now expects full-year adjusted sales to be flat to down 6% at constant exchange rates, an improvement on its previous outlook of down 4-12%. By any reading, that is a softening. And the market punished the stock for it: U.S.-listed shares fell about 6% the same day.

The disappointment was more nuanced than a bad quarter. It came from the direction of travel. Q2 earnings per share of $0.78 missed the consensus estimate of $0.80. More damaging, the Wegovy oral pill, which Novo Nordisk has pinned its hopes on as the next growth engine, generated just 3.2bn kroner in the quarter, slightly below the roughly 3.3bn kroner analysts expected. The pill has exceeded 5m prescriptions since its January launch, says the company's chief executive, Maziar Mike Doustdar. That is respectable uptake, but not the breakout trajectory investors had modelled.

The structural pressures are clear. The company cited intensifying competition, reduced Medicaid coverage for obesity medicines, and lower realised prices in America, partly due to a "most favoured nation" drug-pricing agreement struck with President Donald Trump. That deal ties Novo Nordisk's U.S. prices to those in other countries, squeezing margins in the market where the bulk of GLP-1 profits are made. The incentive behind the policy is familiar: transfer surplus from profitable firms to public budgets. The consequence, less often acknowledged, is that it reduces the return on the expensive research and development required to bring new drugs to market. Fewer pills are launched when the reward for launching them is diminished.

For all the attention that antitrust disputes have drawn, the competition Novo Nordisk faces is not from compounders. It is from Eli Lilly, which has its own GLP-1 products with similar efficacy and a different molecular structure. The two firms have, in effect, a duopoly. Duopolies are not inherently anticompetitive, but they do invite scrutiny of whether profits stem from innovation or from scarcity. In this case the former: both drugs represent genuine therapeutic advances, and both firms are expanding manufacturing capacity rapidly. The real bottleneck is production, not pricing power.

AInvest's aggregate signal labels Novo Nordisk a Hold, with a strong fundamental rating but no directional enthusiasm. That is consistent with a company whose best years of pure growth are behind it, but whose earnings power remains formidable. The stock trades well below its 52-week high of $64, around $46, having seen a maximum drawdown of more than 50% in March. The gap between where the stock is and where street targets cluster near $73 implies that investors who believe the pill and higher-dose formulations will reaccelerate still have room. Those who fear structural margin erosion in America do not.

The broader lesson is about what kind of protection drugmakers actually need. Legal victories against compounders are pyrrhic because the regulatory architecture was never designed to tolerate mass-produced copies of branded drugs. The FDA's proposed rule, if finalised, would remove any remaining ambiguity. What Novo Nordisk and Eli Lilly need instead is a predictable pricing environment in which the returns to innovation remain commensurate with the cost and risk of development.

Medicaid cuts and international price pegs threaten to turn the GLP-1 gold rush into a margin squeeze. That would be a mistake. The drugs work, the market is vast, and the competition is genuine. Taxing it into mediocrity benefits no one. Better to let the duopoly compete.